Tendinopathy isn't tendinitis — and why that distinction changes how it heals
8 min read · Uplevel editorial
Your Achilles has been wrong for eight months. Not injured-wrong, not limping-wrong — just tight in the morning, tender when you press on it, stiff for the first quarter mile before it loosens up. You've iced it. You've taken ibuprofen. You've rested it for stretches of two or three weeks. Each time you come back, it's a little better for a few days and then exactly where it was. Your sports medicine provider calls it tendinitis and tells you to rest more and anti-inflame. You rest more. You anti-inflame. Eight months later the Achilles is still wrong.
The problem might be the diagnosis — not the provider, the word. Tendinitis means inflammation of the tendon. The suffix "itis" is medical shorthand for inflammation, and it carries an implied treatment logic: reduce the inflammation, and the tendon will heal. For an acute tendon injury — a sudden overload that caused tissue damage in the last few days — that logic has some relevance. But for a tendon that's been painful for months, the pathology is almost certainly different, and treating it as if it were inflammatory is why the ibuprofen and the rest aren't working.
What chronic tendon pain almost always represents is tendinopathy — a degenerative process rather than an inflammatory one. The distinction isn't semantic. When researchers have taken biopsies of chronically painful tendons — Achilles, patellar, lateral epicondylar (the tendon involved in tennis elbow), supraspinatus — and examined them under the microscope, what they find consistently is not the cellular infiltrate that defines inflammation. There are no significant populations of inflammatory cells. What there is instead: disorganized collagen architecture, failed healing attempts that resulted in fibrous tissue laid down at wrong angles, aberrant neovascularization (new blood vessel formation that doesn't appear to be functional), and a population of cells called tenocytes that have changed their morphology in ways consistent with chronic degenerative stress. This is not tendinitis. It's a different condition with a different biology, and treating it requires understanding that biology.
The collagen story is particularly important. Healthy tendon is densely packed parallel collagen fibers, organized along the axis of load so that mechanical stress is transmitted efficiently. Damaged tendon that heals incompletely forms scar tissue with disorganized collagen — fibers running in multiple directions, weaker, less elastic, less capable of transmitting load without micro-tearing again. The tissue isn't inflamed; it's structurally compromised. You can't reduce collagen disorganization with ibuprofen. You can't rest it back into proper alignment.
This is why anti-inflammatory interventions don't produce lasting improvement in chronic tendinopathy, and why rest consistently fails as a long-term treatment. Rest removes the load that's causing pain, which produces short-term relief. When you return to activity, the structurally compromised tissue meets load again, and the same micro-damage cycle restarts. The tendon hasn't gotten better — you've just been avoiding the position that reveals how compromised it is.
What does work, and what the research supports most clearly, is progressive mechanical loading — specifically eccentric and isometric protocols. Eccentric loading means contracting the tendon while it's lengthening: the classic Achilles eccentric protocol involves lowering your heel slowly off a step, letting the calf muscle and Achilles work under controlled tension through the lengthening phase. Isometric loading means sustained contraction without movement. Both approaches have one thing in common: they apply controlled mechanical stress to the tendon in a way that stimulates tenocyte activity and collagen remodeling without creating the destructive overload that causes micro-tearing. The signal you're sending with progressive loading is: reorganize this collagen, lay down new fibers with correct alignment, strengthen this tissue.
The honest time horizon for this process is twelve to twenty-four weeks. That's not a typo. Tendinopathy recovery, done correctly, takes the better part of a year. Tendon tissue remodels slowly — it has a slower metabolic rate and lower cell turnover than muscle, which is part of why it's vulnerable to degenerative change in the first place. Improvement happens in small increments, and the path is rarely linear. There are weeks where the tendon feels better and weeks where it doesn't, often without obvious cause. The psychological challenge of treating a condition that requires months of work and offers imperfect feedback is part of the clinical picture.
Root causes matter enormously, and they're often missed in the tendinopathy conversation. A patellar tendon that keeps breaking down is rarely just a patellar tendon problem — it's frequently a hip abductor weakness problem, or a quad-to-hamstring imbalance, or a training load management problem where someone's mileage increased too fast for their tendon to adapt. Tennis elbow is often downstream of wrist mobility limitations and forearm muscle imbalances. The supraspinatus doesn't degenerate in isolation from the mechanics of the whole shoulder. Getting the loading protocol right and ignoring the upstream cause is a way to spend twelve weeks doing the right exercise and still not resolving the problem.
Where peptides like BPC-157 and TB-500 enter the conversation is as a potential support for the regenerative environment that progressive loading is trying to create. The hypothesis — and it's a hypothesis, not a proven clinical fact — is that for tendons whose biology has stalled in chronic degenerative change, an angiogenic signal (BPC-157's primary researched mechanism) and a cell migration signal (TB-500's primary researched mechanism) may help re-initiate the remodeling process that loading is trying to drive. In animal models, BPC-157 has been studied for its role in tendon healing and collagen synthesis. TB-500 has been explored for cellular migration to injury sites and anti-inflammatory modulation. The animal data is reasonably compelling; the human clinical trial data is sparse. Your prescribing provider would be having this conversation with you as a research-informed possibility, not a proven protocol.
The compounded peptide conversation belongs after the basics are in place, not instead of them. Progressive loading is the intervention with the most consistent human evidence for chronic tendinopathy. Addressing root mechanical causes is non-optional. Sleep, nutrition, and systemic recovery quality matter for tissue remodeling at a basic level. Peptides, if they have a role here, have it as one component of a comprehensive approach — a potential signal nudge in tissue that's been waiting for one — not as a standalone fix.
What changes when you get the diagnosis right is the entire treatment logic. If your chronic Achilles pain is tendinitis, you rest and anti-inflame. If your chronic Achilles pain is tendinopathy, you load progressively, address the upstream mechanics, give it months, and consider whether the regenerative environment needs additional support. Those are different strategies with different time horizons and different success rates. The word matters. The biology behind the word matters more. Eight months of treating tendinopathy like tendinitis is eight months of applying the wrong answer to the right question — and the Achilles just keeps telling you, every morning when you take your first step, that it hasn't gotten the answer it needs.